Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics Holdings, Inc. (AMEX: SENS) has announced plans to release its third quarter 2021 financial results on November 9, 2021, after market close. A conference call will be held at 4:30 p.m. Eastern Time to discuss the company's performance for the quarter. Investors can access the webcast through Senseonics' website. The company specializes in developing long-term, implantable continuous glucose monitoring systems aimed at improving diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to 11 new non-executive employees as of October 1, 2021. A total of 74,000 non-qualified stock options were granted at an exercise price of $3.45 per share, the closing price on the grant date. The options vest 25% on the first anniversary of employment, with the remainder vesting monthly over three years, dependent on continued service. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management.
The University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio, has commenced offering the Eversense® Continuous Glucose Monitoring (CGM) System to Medicare enrollees as of early September 2021. This initiative aims to improve diabetes management among patients with type 1 and type 2 diabetes who are on insulin. The Eversense CGM System, which features a long-term implantable sensor and a smart transmitter, enhances patient experience and supports better health outcomes, as emphasized by Betul Hatipoglu, M.D. at UHACO.
Senseonics Holdings, Inc. (NYSE American: SENS), specializing in long-term, implantable continuous glucose monitoring systems, plans to participate in the virtual H.C. Wainwright Global Investment Conference. Management will engage in one-on-one meetings on September 15, 2021, with a presentation webcast available starting September 13, 2021, at 7:00 AM ET. Access to the on-demand webcast will be provided on the company’s website. Senseonics is dedicated to transforming diabetes management with its Eversense® CGM products, which offer real-time glucose data via a mobile app.
Senseonics Holdings reported second quarter 2021 revenue of $3.3 million, significantly up from $0.26 million in Q2 2020. U.S. revenue was $0.98 million, while international revenue reached $2.31 million. The company raised $50 million through an equity offering, mainly for debt service. However, net loss expanded to $180.32 million or $0.42 per share, largely due to increased accounting charges. Senseonics projects 2021 global net revenue between $12 million to $15 million.
Senseonics Holdings, Inc. (NYSE-American: SENS) has announced its plan to release second quarter 2021 financial results on August 9, 2021, after market close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss its performance, with a concurrent webcast available on their website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, such as the Eversense and Eversense XL, which provide real-time glucose data to users via a smartphone app.
Senseonics Holdings has granted equity to new employees as per its 2019 Inducement Plan. On July 1, 2021, the Compensation Committee approved 66,000 non-qualified stock options for five new non-executive employees, with an exercise price of $3.50 per share. The vesting schedule includes 25% on the first anniversary of their start date and the rest monthly over three years, contingent on continued service. The company aims to expand its Eversense continuous glucose monitoring (CGM) system for diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) presented new data from the PROMISE Study regarding its Eversense CGM System at the American Diabetes Association’s 81st Annual Scientific Sessions. The findings indicate that the next-generation device demonstrates safety and accuracy comparable to the current 90-day sensor with extended usage up to 180 days. Key metrics include a mean absolute relative difference (MARD) of 9.1% and high hypoglycemia alert detection rates. The Eversense system enhances user experience by offering discreet alerts and a rechargeable transmitter.
Senseonics Holdings (SENS) announced positive results from the PROMISE Study for its Eversense CGM System, showcasing its accuracy and safety over a 180-day period. The study revealed an overall mean absolute relative difference (MARD) of 9.1% for the primary sensor and a 93% hypoglycemic alert detection rate. The company is awaiting regulatory feedback from US and European agencies regarding its pre-market submissions. The Eversense CGM System, now available in the US and Europe, is significant for patients managing diabetes.
Senseonics Holdings reported financial results for Q1 2021, with revenues reaching $2.85 million, a significant increase from $0.04 million in Q1 2020. Revenue outside the U.S. accounted for $2.53 million. Notably, the company decreased its operating loss by $32.52 million year-over-year, while net loss rose to $249.51 million, largely due to non-cash accounting charges. Senseonics expects 2021 global net revenue between $12 million and $15 million. The company also strengthened its balance sheet by raising $175 million from financing transactions.